C Kahlert1,2, A Bregenzer3, C Gutmann3, S Otterbech3, M Hoffmann3, P Schmid3, P Vernazza3. 1. Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland. christian.kahlert@kssg.ch. 2. Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland. christian.kahlert@kssg.ch. 3. Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland.
Abstract
BACKGROUND: Antiretroviral treatment (ART) with ritonavir-boosted protease inhibitor monotherapy (rb-PMT) remains a potentially attractive strategy for treatment simplification in HIV-infected individuals. However, long-term follow-up in particular with respect to HIV-RNA suppression in cerebrospinal fluids (CSF) is still lacking. METHODS: Patients who participated in one of the three monotherapy trials [indinavir/r, ATARITMO (atazanavir/r), MOST (lopinavir/r)] at our HIV clinic and remained successfully suppressed during the entire trial (plasma < 50 copies/mL, CSF < 100 copies/mL) were offered to continue their monotherapy under close monitoring. While on rb-PMT, patients were asked to provide CSF samples in yearly or 2-yearly intervals. All patients fully suppressed in plasma and CSF for at least 12 months were included in the analysis. Patients demonstrating any failure in plasma or CSF resumed triple combined ART. RESULTS: A total of 27 patients (5 women and 22 men) fulfilled the entry criteria. The median follow-up time was 4.8 (1.1-10.9) years with an overall experience of 139 patient-years on monotherapy. Eleven of 27 (41 %) patients (2 women and 9 men) developed virologic failure (1 in plasma only, 4 in CSF only, 4 both in plasma and CSF and 2 in plasma with CSF not available). Plasma failure occurred in 7 patients after a median follow-up of 25 (13-32) months, and CSF failure in 8 patients after a median follow-up of 30 (14-64) months. Seven patients are still on rb-PMT with atazanavir/r. Failure was associated with shorter duration of fully suppressed plasma viral load prior to starting (p < 0.022). CONCLUSION: For selected patients, rb-PMT might be a valid long-term treatment strategy. Nevertheless, even after 12 months of full HIV-RNA suppression, more than 1/3 of patients may still develop failure in either plasma or CSF. Given the observation of isolated CSF failure, treatment monitoring with regular lumbar puncture should be recommended in rb-PMT. Only monotherapy with atazanavir/r was successful beyond 39 months. Monotherapy failure was significantly associated with a shorter duration of complete HIV-RNA suppression in plasma prior to rb-PMT start. Further investigation is needed to better identify predictors for patients that will qualify for successful long-term rb-PMT.
BACKGROUND: Antiretroviral treatment (ART) with ritonavir-boosted protease inhibitor monotherapy (rb-PMT) remains a potentially attractive strategy for treatment simplification in HIV-infected individuals. However, long-term follow-up in particular with respect to HIV-RNA suppression in cerebrospinal fluids (CSF) is still lacking. METHODS:Patients who participated in one of the three monotherapy trials [indinavir/r, ATARITMO (atazanavir/r), MOST (lopinavir/r)] at our HIV clinic and remained successfully suppressed during the entire trial (plasma < 50 copies/mL, CSF < 100 copies/mL) were offered to continue their monotherapy under close monitoring. While on rb-PMT, patients were asked to provide CSF samples in yearly or 2-yearly intervals. All patients fully suppressed in plasma and CSF for at least 12 months were included in the analysis. Patients demonstrating any failure in plasma or CSF resumed triple combined ART. RESULTS: A total of 27 patients (5 women and 22 men) fulfilled the entry criteria. The median follow-up time was 4.8 (1.1-10.9) years with an overall experience of 139 patient-years on monotherapy. Eleven of 27 (41 %) patients (2 women and 9 men) developed virologic failure (1 in plasma only, 4 in CSF only, 4 both in plasma and CSF and 2 in plasma with CSF not available). Plasma failure occurred in 7 patients after a median follow-up of 25 (13-32) months, and CSF failure in 8 patients after a median follow-up of 30 (14-64) months. Seven patients are still on rb-PMT with atazanavir/r. Failure was associated with shorter duration of fully suppressed plasma viral load prior to starting (p < 0.022). CONCLUSION: For selected patients, rb-PMT might be a valid long-term treatment strategy. Nevertheless, even after 12 months of full HIV-RNA suppression, more than 1/3 of patients may still develop failure in either plasma or CSF. Given the observation of isolated CSF failure, treatment monitoring with regular lumbar puncture should be recommended in rb-PMT. Only monotherapy with atazanavir/r was successful beyond 39 months. Monotherapy failure was significantly associated with a shorter duration of complete HIV-RNA suppression in plasma prior to rb-PMT start. Further investigation is needed to better identify predictors for patients that will qualify for successful long-term rb-PMT.
Authors: D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano Journal: Nat Med Date: 1999-05 Impact factor: 53.440
Authors: A Mondi; M Fabbiani; N Ciccarelli; M Colafigli; A D'Avino; A Borghetti; R Gagliardini; R Cauda; A De Luca; S Di Giambenedetto Journal: J Antimicrob Chemother Date: 2015-02-26 Impact factor: 5.790
Authors: Ignacio Pérez-Valero; Alicia González-Baeza; Miriam Estébanez; Susana Monge; María L Montes-Ramírez; Carmen Bayón; Federico Pulido; José I Bernardino; Francisco X Zamora; Juan J González-García; María Lagarde; Asunción Hernando; Francisco Arnalich; José R Arribas Journal: Clin Infect Dis Date: 2014-08-11 Impact factor: 9.079
Authors: Renaud A Du Pasquier; Samantha Jilek; Malela Kalubi; Sabine Yerly; Christoph A Fux; Christine Gutmann; Alexia Cusini; Huldrych F Günthard; Matthias Cavassini; Pietro L Vernazza Journal: AIDS Date: 2013-01-14 Impact factor: 4.177
Authors: Ronald J Ellis; David J Moore; Meredith E Childers; Scott Letendre; J Allen McCutchan; Tanya Wolfson; Stephen A Spector; Karen Hsia; Robert K Heaton; Igor Grant Journal: Arch Neurol Date: 2002-06
Authors: Amanda Clarke; Veronika Johanssen; Jan Gerstoft; Bonaventura Clotet; Diego Ripamonti; Andrew Murungi; Ceyhun Bicer; Maria Blanca Hadacek; Christiane Moecklinghoff Journal: J Int AIDS Soc Date: 2014-11-02 Impact factor: 5.396
Authors: Alejandro Arenas-Pinto; Wolfgang Stöhr; Amanda Clarke; Ian Williams; Nicholas J Beeching; Jane Minton; Vincent Lee; Nicholas I Paton Journal: Antivir Ther Date: 2017-02-24